Intuitive Surgical (ISRG) Beats Q1 Expectations. The Bull Case Builds

Intuitive Surgical (ISRG) remains an attractive long-term story following another strong quarter. The Q1 results released on April 21 reinforced the durability of its growth model. The leader in minimal invasive care continues to benefit from a powerful combination of recurring procedure revenue, ongoing system and technology adoption, and platform expansion, all of which build on one another over time.

Even with the stock still trading at what appears to be a premium, the Q1 print strengthened the case that Intuitive’s moat, growth profile, and long-term earnings power remain hard to match. That is why I stay bullish on the stock.

A Masterclass in Recurring Revenue

Intuitive’s Q1 report was a rather clear response to those who thought the robotic surgery narrative had started to cool off. Intuitive came in with $2.77 billion in revenue, up 23% from a year ago, which is strong on its own. However, the more important part of the quarter was not just the top-line beat. It was the mix. It is incredible to see how much of the business now comes after the initial system sale.

Hospitals may buy the da Vinci 5 platform upfront, but the better engine is the steady stream of revenue from instruments and accessories tied to every procedure. That segment reached $1.69 billion this quarter, up 23% year-over-year, underscoring the model’s durability. That is what makes the business so powerful, in my view.

Once these systems are installed, they tend to keep generating high-margin follow-on revenue over time. You can see that in the margin profile as well, with operating margins rising to nearly 31%. So the story here is not just that Intuitive is still growing. It is that the recurring side of the business keeps getting stronger as the installed base expands.

I also liked management’s comments on procedural growth. They acknowledged that growth is normalizing, but the actual volume still rose at a double-digit rate. Selling the robot is just the first step. The real question now is how much those machines are getting used after they’re in place. That is where the model’s real strength shows up. Recurring revenue grows as utilization rises, and each addition to the installed base makes the business a little more durable. As Intuitive moves closer to the 12,000-system mark, the cash-flow foundation continues to strengthen.

The Intelligence in the Machine

To expand on that point, I believe that the investment case for ISRG will increasingly center on the “digital brain” built into the da Vinci 5 as we move forward. During the earnings call, management leaned heavily into the adoption of their tissue analytics driven by artificial intelligence (AI) and force-feedback systems. This is likely to reduce the variability of human error.

When a surgeon can get real-time data on the pressure they’re applying to a delicate vessel, clinical outcomes improve, and the hospital’s cost of care drops. That’s the “quintuple aim” they keep talking about, and it’s likely to prove a massive growth lever as hospitals look to squeeze efficiency out of every square inch of the operating room (OR).

We also have to consider the long-tail potential of the Ion system and the Single Port (SP) platform. While the flagship da Vinci gets the glory, the Ion is quietly dominating the lung biopsy space, growing at a clip that outpaces almost everything else in the portfolio. In fact, Ion procedures grew about 39% in Q1. The industry is naturally shifting toward these minimally invasive, data-heavy procedures, and Intuitive is already 10 years ahead of the competition in clinical evidence, which means strong growth will persist.

The Price of a Permanent Moat

This brings us to the valuation, because a high-growth company of this caliber and quality doesn’t come cheap. At a forward P/E of roughly 45x 2026 expected earnings per share (EPS), ISRG is hardly a “value” play. It’s surely a premium multiple for a company that has, admittedly, lagged behind some of its high-flying tech peers over the last few months. However, that’s exactly why I think it’s a strong buy today.

The market has been so obsessed with pure-play AI software that it’s discounted the physical AI, that is, the robots that actually perform life-saving tasks. This slight “lag” in the stock price has created a rare entry point for a company that dominates this category.

When considering the moat, we have to talk about the muscle memory. Tens of thousands of surgeons have spent their entire careers training on Intuitive’s interface. Switching to a competitor sounds like a nightmare. That kind of lock-in is priceless. Moreover, with EPS growth projected to stay in the mid-to-high teens for the foreseeable future, today’s rich multiple starts to look a lot more reasonable. This is especially true, as AI capabilities may shift from a “feature” to a high-margin software service.

Is ISRG Stock a Buy, Sell, or Hold?

Despite its underwhelming performance, Intuitive Surgical features a Strong Buy consensus rating on Wall Street. This is based on 15 Buy and five Hold ratings. Notably, no analyst rates the stock a Sell. In addition, ISRG’s average price target of $580.20 implies about 21% upside over the next 12 months, suggesting the stock’s valuation may not be as rich as it initially appears.

Conclusion

Intuitive already has the footprint of an incumbent, but it is still growing with the energy of a company in its early stages. That is what makes it so interesting. Yesterday’s results showed that the model is still strengthening, with recurring revenue and procedure growth supporting the bullish case. The valuation is not cheap, but businesses this good rarely are.